# US 9,006,399 B2 · Anti-OX40 antibodies and methods of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,006,399 B2
- Document ID: US9006399B2
- Status: Granted
- Kind: B2
- Application number: 13/818,645
- Filed: 2011-08-23
- Published: 2013-10-24
- Granted: 2015-04-14
- Earliest claimed: 2010-08-23
- Assignees: Board of Regents, The University of Texas System
- Applicants: Yong-Jun Liu; Kui Shin Voo; Laura Bover; Naoya Tsurushita; J. Yun Tso; Shankar Kumar
- Inventors: Yong-Jun Liu; Kui Shin Voo; Laura Bover; Naoya Tsurushita; J. Yun Tso; Shankar Kumar
- Web page: https://patentgrep.com/patent/US9006399B2

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

## Claims

### Claim 1

An isolated antibody or antigen-binding portion thereof which binds to OX40 comprising:
(a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:1;
(b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:2;
(c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:3;
(d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO:7; (e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO:8; and
(f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO:9.

### Claim 2 (depends on 1)

An isolated antibody or antigen-binding portion thereof according to claim 1, wherein the isolated antibody comprises a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:10 and a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:4.

### Claim 3 (depends on 2)

The isolated antibody or antigen-binding portion thereof of claim 2, wherein the isolated antibody comprises a light chain variable region having the amino acid sequence of SEQ ID NO:10 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:4.

### Claim 4 (depends on 1)

The isolated antibody or antigen-binding portion thereof of claim 1, comprising a light chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:11 and a heavy chain variable region having a sequence at least 90% identical to the amino acid sequence of SEQ ID NO:5.

### Claim 5 (depends on 4)

The isolated of antibody or antigen-binding portion thereof of claim 4, comprising a light chain variable region having the amino acid sequence of SEQ ID NO:11 and a heavy chain variable region having the amino acid sequence of SEQ ID NO:5.

### Claim 6 (depends on 1)

An isolated antibody or antigen-binding portion thereof of claim 1, wherein the isolated antibody is a monoclonal antibody.

### Claim 7 (depends on 6)

The isolated antibody or antigen-binding portion thereof of claim 6, wherein the isolated monoclonal antibody is a humanized antibody.

### Claim 8 (depends on 1)

An antigen-binding portion of an antibody according to claim 1, wherein the antigen-binding portion retains the ability to specifically bind and agonize OX40 receptor.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the antibody or antigen-binding portion thereof of claim 1.